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Objectives: To compare the prognostic value of FENOwith bronchoprovocation testing when the
clinical course within the first year after assessment was taken into account; to compare the
prognostic values with respect to eosinophilic versus non-eosinophilic inflammatory pattern.
Methods: Cross-sectional diagnostic study with a delayed-type reference standard in 393 pa-
tients attending a private practice of pneumologists with complaints suspicious of obstructive
airway disease. Index test: FENO measurement. Reference standard: ratio FEV1/VC or airway
resistance assessed by body plethysmography, with additional bronchoprovocation or broncho-
dilator testing, as well as spontaneous sputum (smear slides). This was combined with a follow-
up evaluation by a structured interview after 12 months.
Results: 302 (76.8%) patients were reached for follow-up. Regarding asthma diagnosis, the area
under the curve (AUC) for FENO was 0.603 (95%CI 0.528e0.677) for the whole group. With eosin-
ophilic asthma as target, AUC increased (0.819 (95%CI 0.703e0.934)) and exceeded that of
bronchoprovocation (0.711 (95%CI 0.584e0.874)). FENO showed no diagnostic value in non-
eosinophilic asthma. In patients reporting wheezing and allergic rhinitis at the initial assess-
ment, its positive predictive value was 90.9% (95%CI 62.3%e98.4) at a cut-off of 45 ppb, and
100% (95%CI 56.6e100%) at 81 ppb.General Practice, Klinikum rechts der Isar, Technische Universita¨t Mu¨nchen, Orleansstrasse 47, 81667
58913; fax: þ49 89 614658915.
r@tum.de (A. Schneider).
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Prognostic value of bronchial provocation and FENO measurement 35Conclusions: FENO bears limited information when measured non-specifically in primary care,
but is useful for diagnosing eosinophilic asthma. If sputum is not available, information on
wheezing and rhinitis can narrow down the range of patients in whom FENO is informative. More-
over, the evaluation of the clinical value of FENO benefits from taking into account follow-up
data to confirm the diagnosis.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Asthma is a common chronic disorder in the industrialised
countries [1]. It is characterised by chronic inflammation,
bronchial hyper-responsiveness (BHR) and usually revers-
ible airway obstruction. Spirometry is considered as a
reference standard for diagnosing airway obstruction [2],
however it can be difficult to recognise mild asthma, as
obstruction is not continuously present [3]. Therefore
bronchoprovocation for determining BHR remains as a
reference standard, particularly in case of inconclusive
spirometric results [4]. It is considered valuable in con-
firming or excluding asthma, despite being time-consuming,
costly, not everywhere available and carrying a small risk of
severe bronchospasm [5]. Compared to that, fractional
exhaled nitric oxide (FENO) is an easily available, fully non-
invasive marker, and increased FENO has been consistently
demonstrated in asthma, including mild asthma [6,7]. The
major pathophysiological basis is that nitric oxide modulate
airway hyperresponsiveness [8] and is associated with
eosinophilic inflammation [9]. Therefore, FENO has a po-
tential for establishing or confirming the diagnosis safely
and fast in general practice and practices of pneumologists.
The diagnostic accuracy of FENO for asthma has been
investigated in numerous studies. In general, despite
promising results there were also conflicting data, possibly
related to different inflammatory patterns [10,11]. For
practical purposes, airway inflammation can be categorised
into eosinophilic and non-eosinophilic, with some overlap.
Recently we found that FENO was increased in patients with
asthma and eosinophilic inflammation, but decreased in
neutrophilic inflammation [11]. To which extent this affects
the diagnostic accuracy of FENO and how to deal with it in
clinical practice, is currently unclear.
In the previous study we addressed these questions by
evaluating only the information available at the time of
diagnosis [11]. The present analysis had the primary aim to
compare the prognostic value of FENO with that of bron-
choprovocation taking into account the additional infor-
mation from the clinical course within the first year after
the diagnostic assessments. The secondary aim was to
compare the subgroups with eosinophilic versus non-
eosinophilic inflammatory pattern.Methods
Design and sample
We conducted a cross-sectional diagnostic study with a
delayed-type reference standard [12] in a large privatepractice led by five pneumologists. From June 2010 to
October 2011 (time t0) 393 patients presenting for the first
time with complaints suggestive of asthma were consecu-
tively included. Inclusion criteria were the presence of
symptoms such as dyspnoea, cough or phlegm for more than
two months, leading to the clinical suspicion of obstructive
airway disease (‘indicated population’). Patients were
advised not to smoke at the day of assessment. If they were
already using inhaled medication (e.g. prescribed by a
general practitioner before referral), they were advised not
use it for 12 h prior to the assessments. Details of the
diagnostic procedures are described elsewhere [11].
Follow-up
Twelve months (time t1) after the initial assessments, pa-
tients were called by telephone and interviewed with
respect to clinical signs and symptoms. They were asked
whether they still suffered from obstructive airway disease,
or still felt healthy when obstructive disease had been
excluded at t0. Additionally, they were asked whether they
still used medication, and if so, which one. At t1 we also
contacted the general practitioners (GP) and the pneu-
mologists of the patients and asked them whether in their
opinion the patient was still suffering from obstructive
airway disease (OAD) and which medication had been pre-
scribed, both actually and during the last year. Patients
were included for follow-up analysis when data could be
completed in this manner, in particular when the patient
and the respective GP were reached by phone. The pneu-
mologist was reached in each case.
Data analysis
Baseline data for the follow-up patients is presented
descriptively. Differences between lung function indices,
age and packyears (not normally distributed) were tested
with the ManneWhitney-U-test or KruskaleWallis-test. Dif-
ferences between clinical symptoms were calculated with
the Chi-square-test. Receiver operating characteristic
(ROC) curves were plotted for graphical illustration of
sensitivity and specificity, especially a comparison between
FENO and methacholine. The cut-off points were compared
with respect to their predictive value. Confidence intervals
were calculated using Wilson’s method [13]. The Krus-
kaleWallis-test was employed to compare FENO values be-
tween patterns of airway inflammation. PPV and NPV of
FENO were investigated in subgroups of patients with
distinct clinical signs and symptoms in an exploratory
manner. Data analysis was done using SPSS 21 for Windows,
and the level of statistical significance assumed at pZ 0.05.
36 A. Schneider et al.Based on a previous study, we estimated the pre-test
probability of asthma as 35% [14]. Using a cut-off value of
46 ppb, FENO sensitivity had been found to be 32% and
specificity 93% [15]. Power calculations based on this
showed that we needed at least 302 patients to determine
sensitivity and specificity with 95% confidence intervals of
9% [16].Results
Study population
A total of 400 patients (235 [59.8%] female) entered the
study (t0) and 393 had been initially included (data of 7
patients incomplete). According to lung function and
bronchoprovocation tests, 154 patients (39.2%) had asthma,
5 (1.3%) COPD, and 234 (59.5%) no OAD. Bronchoprovoca-
tion was performed in 369 patients (93.9%); in 145 (36.9%)
the diagnosis of asthma was based on bronchoprovocation,
in 9 (2.2%) on bronchodilation. Details of the study popu-
lation at baseline have been given previously [11]. The
telephone follow-up reached 344 patients and the GPs of
335 patients, with information from both patients and GPs
in 302 (76.8%) patients (Fig. 1). In 33 (10.9%) of the 302
patients with complete follow-up data, patients with pre-
viously diagnosed asthma and their GPs agreed that there
were no symptoms or signs of asthma any more after 12
months. Four (1.3%) patients and their GPs stated that
asthma was present despite its exclusion at t0; these pa-
tients were taking inhaled asthma medication continuously.
Therefore 83 (27.5%) of the 302 patients suffered from
asthma at t1, while 219 patients did not have asthma
(Table 1). Among the latter, 8 were diagnosed as having
restrictive lung disease, 7 chronic bronchitis (withoutFigure 1 Flow chart of diagnostairway obstruction), 6 BHR, 4 vocal cord dysfunction, 3
COPD; no chronic respiratory disease was found in the
remaining 191 patients. Regarding clinical signs and symp-
toms, differences between asthmatics and non-asthmatics
were most pronounced for wheezing (65.1% vs. 36.5%) and
‘suffering from nasal allergies’ (51.8% vs. 21.9%).
Overall, 91 patients (23.2%) could not be included into
the follow-up analysis due to missing data. Non-responders
were significantly younger (39.4 vs. 44.5 yrs; p Z 0.006),
with similar distribution of gender (pZ 0.493). There were
tendencies that the proportion with a diagnosis of asthma
at t0 was higher in non-responders (46.2% vs. 37.1%;
p Z 0.08), as well as FENO values (38.7 vs. 27.2 ppb;
p Z 0.092). There were no statistically significant differ-
ences in the lung function indices FEV1, VC and FEV1/VC
(non-responder not contained in Table 1).
Among the 302 patients, 103 (34.1%) had delivered
sputum upon inclusion (t0). Of these, 39 (37.9%) showed
predominantly eosinophilic cells in sputum, 13 (12.6%)
neutrophilic cells; 50 (48.5%) patients presented aero-
digestive cells; one showed a lymphocytic pattern. Seven-
teen (43.6%) patients with eosinophilic pattern, 2 (15.4%)
with neutrophilic pattern, 14 (28%) with aerodigestive and
the patient with lymphocytic pattern suffered from asthma
(Table 2). Patients with eosinophilic pattern significantly
more often suffered from wheezing and allergic rhinitis.
They showed the highest FENO values, higher BHR and
slightly more airway obstruction compared to patients with
non-eosinophilic asthma.
Diagnostic accuracy of FENO
ROC analyses are illustrated in Fig. 2. The area under the
curve (AUC) of bronchoprovocation in relation to the diag-
nosis “asthma yes/no” after 12 months (t1) was 0.715 (95%ic investigation and follow-up.
Table 1 Characteristics of the study population at follow-up, twelve months after inclusion into the study (t1). Values
indicate the number (proportion) or mean [sd].
Asthma t1 No asthma t1 p-Value
n (%) 83 (27.5) 219 (72.5)
Female 50 (60.2) 130 (59.4) 1.000
FENO (mean in parts per billion [sd]) 36.6 [37.7] 23.7 [21.3] 0.006
Age (mean in years [sd]) 41.9 [15.4] 45.5 [16.3] 0.089
FEV1 (mean of absolute values in litre [sd]) 3.23 [0.87] 3.40 [0.97] 0.180
FEV1 (mean of % of predicted [sd]) 100.8 [16.0] 107.3 [16.0] 0.002
VC (mean of absolute values in litre [sd]) 3.94 [1.01] 3.97 [1.18] 0.850
VC (mean of % of predicted [sd]) 103.9 [15.9] 104.8 [16.8] 0.658
FEV1/VC (mean of % [sd]) 81.2 [8,5] 85.2 [7.2] <0.001
Do you ever suffer from shortness of breath? (yes) 57 (68.7) 116 (53.0) 0.011
Do you ever suffered from wheezing in your chest? (yes) 54 (65.9) 80 (36.7) <0.001
Do you often suffer from a cough? (yes) 36 (43.4) 110 (50.2) 0.520
Do you often suffer from expectoration? (yes) 26 (31.3) 59 (26.9) 0.337
Have you ever woken up with a feeling of
tightness in your chest? (yes)
23 (27.7) 60 (27.4) 0.839
Have you ever been woken up by an attack of
shortness of breath? (yes)
21 (25.3) 31 (15.2) 0.007
Do you suffer from any nasal allergies? (yes) 43 (51.8) 48 (21.9) <0.001
Do you smoke (yes) 8 (9.6) 23 (10.5) 0.668
Did you previously smoke? (yes) 28 (33.7) 83 (37.9) 0.833
How much do/did you smoke? [mean in pack year (SD)] 10.1 [9.4] 12.3 [15.4] 1.000
p-value related to ManneWhitney-U-test or Chi-square-test.
Prognostic value of bronchial provocation and FENO measurement 37CI 0.643e0.778) for the 302 completers. In these patients
the AUC of bronchoprovocation related to the diagnosis at
inclusion (t0) was 0.671 (95%CI 0.603e0.739; p < 0.001)
(data not in Fig. 2). The AUC of FENO at t1 was 0.603 (95%CI
0.528e0.677) and thereby lower than the corresponding
AUC of bronchoprovocation (AUC for FENO at t0 was 0.656;
95%CI 0.600e0.712; p < 0.001[9]). At t1, the highest sum of
sensitivity (47.0%; 95%CI 36.6e57.6%) and specificity
(73.1%; 95%CI 66.8e78.5%) was achieved at a cut-off point
of 26 ppb NO, with a PPV of 39.8% (95%CI 30.7e49.7%) and
NPV of 78.4% (95%CI 72.3e83.5%).Table 2 Characteristics of patients at follow-up (t1) who deliv
between asthma, sputum cells and FENO. Values indicate the nu
Eosinophilic asthm
n (%) 17 (16.5)
FENO (mean in parts per billion [sd]) 44.6 [28.9]
Concentration of methacholine (mg/mL) 0.44 [0.37]
FEV1 (mean of absolute values in litre [sd]) 2.96 [0.88]
FEV1 (mean of % of predicted [sd]) 99.7 [10.2]
VC (mean of absolute values in litre [sd]) 3.68 [0.96]
VC (mean of % of predicted [sd]) 97.8 [16.9]
FEV1/VC (mean of % [sd]) 78.8 [8.8]
Do you smoke (yes) (n [%]) 2 (11.8)
How much do/did you smoke?
[mean in pack year (SD)]
8.38 [1.97]
Suffer from nasal allergies AND
wheezing in chest [n (%)]
7 (41.2)
p-value related to KruskaleWallis-test or Chi-square-test.The AUC of FENO was slightly higher in the patients who
had delivered sputum, but still lower than that of provoca-
tion in this group (0.660 vs. 0.709). However, the AUC of
FENOat t1 considerably increased and even exceeded that of
provocation when eosinophilic asthma (prevalence 16.5%)
was selected as target diagnosis (0.819 vs. 0.711). The
highest sum of sensitivity (82.4%; 95%CI 59.0e93.8%) and
specificity (76.7%; 95%CI 66.8e84.4%) was again reached at
26 ppb, with a PPV of 41.2% (95%CI 26.4e57.8%) and NPV of
95.7% (95%CI 88.0e98.5%). FENO showed no diagnostic value
when non-eosinophilic asthma at t1 was chosen as targetered sputum twelve months before (t0) (n Z 103): Relation
mber (proportion) or mean [sd].
a Non-eosinophilic asthma No asthma p-Value
17 (16.5) 69 (67.0)
25.8 [29.9] 20.9 [15.5] <0.001
0.60 [0.36] 0.84 [0.23] 0.002
3.50 [0.94] 3.37 [0.87] 0.183
102.7 [10.0] 106.2 [8.9] 0.008
4.19 [1.03] 3.99 [1.06] 0.258
108.7 [11.7] 106.6 [15.1] 0.068
83.4 [7.3] 84.3 [7.0] 0.050
1 (5.9) 6 [8.7] 0.929
11.2 [11.0] 13.7 [19.1] 0.966
3 (17.6) 6 (8.7) 0.003
Figure 2 ROC curves of FENO measurement and bronchoprovocation in the follow-up diagnoses of asthma with different patient
samples.
38 A. Schneider et al.diagnosis (AUCZ 0.439; 95%CI 0.286e0.591); also the AUC of
bronchoprovocation was low (0.631; 95%CI 0.485e0.778).
Among the 302 patients, 49 (16.2%) reported recurrent
wheezing and in addition signs of allergic rhinitis. Of these,
29 (59.2%) showed asthma (eosinophilic or non-
eosinophilic). For patients with this combination of symp-
toms (n Z 49), FENO yielded an AUC at t1 of 0.684 (95%CI
0.534e0.833; p Z 0.030). Its PPV to recognise these pa-
tients was 90.9% (95%CI 62.3%e98.4) at a cut-off of 45 ppb,
and 100% (95%CI 56.6e100%) at 81 ppb (data not shown).Discussion
To our knowledge, this is the largest diagnostic-prognostic
study on the use of FENO in a real-life setting of primary
care, where milder forms of diseases are more prevalent
as, e.g. in the hospital or populations recruited for asthma
research. To assess the diagnostic value of FENO, we
investigated a group of patients with suspected obstructive
airway disease by considering clinical information available
until 12 months after the initial assessments. We found that
the overall value of initial FENO to predict the presence of
asthma within 12 months was only moderate. If, however,
the analysis was restricted to patients with initial signs of
airway eosinophilia, the diagnostic accuracy of FENO for
asthma within this time period was high and even exceeded
that of methacholine challenges. In contrast, FENO seemed
not suitable in non-eosinophilic asthma.Previous studies demonstrated some diagnostic accuracy
of FENO for asthma [11,15]. Obviously, its usefulness de-
pends on the pre-test probability which might be very
different in research settings and daily practice. Despite
satisfying sensitivity and specificity, the positive predictive
value might be too low for practical purposes, if the pre-
test probability is low. The relationship between these
probabilities is described by Bayes’ Theorem. Its impact on
diagnostic evaluations is well known [17] and has also been
demonstrated for bronchoprovocation testing [18].
Accordingly, divergent results regarding FENO could be
partially explained by different pre-test probabilities cor-
responding to different patient populations. For instance,
in a previous study in general practice we found a
comparatively high pre-test probability of asthma of 46.9%
in patients with symptoms indicative of asthma [15]. This
might be explained by the selection process of patients who
are willing to participate in the study due to increased
suffering. In the present study performed in a large private
practice of pneumologists, the pre-test probability was only
27.5% which might be explained by a lower threshold for
diagnostic investigation (routine work-up, simple accessi-
bility). This underlines the importance of the selection
process of patients for diagnostic evaluation. One approach
to identify patients in whom FENO measurement might be
useful is to perform a detailed medical history and exami-
nation to control for the pre-test probability.
Our results suggest that the combination of symptoms
and assessments might be a way to increase the information
Prognostic value of bronchial provocation and FENO measurement 39derived from additional measurements of FENO. In partic-
ular wheezing and nasal allergy enabled to narrow the
group with respect to eosinophilic asthma. Fitting to this,
FENO was most valuable to rule in asthma in patients with
eosinophilic inflammatory pattern, in line with previous
studies [19,20]. In these patients FENO was even superior to
bronchoprovocation. In accordance with the literature
[19,20], these patients showed a slightly greater deterio-
ration in FEV1 and more often BHR than patients with non-
eosinophilic asthma. This highlights the presence of
different types of disease in patients with similar symptoms
of asthma. Importantly, eosinophilic asthma could be ruled
out with high certainty (NPVZ 95.7%). This aspect of ruling
out is often ignored but might help the practitioner to avoid
a failure of a trial therapy with inhaled corticosteroids.
FENO had a diagnostic blind spot in non-eosinophilic
asthma. This might be kept in mind when the presence of
asthma is suggested by symptoms and clinical history but
FENO is low. The analysis of spontaneous sputum was an
approach for narrowing down candidate groups but, un-
fortunately, this method is not in widespread use. More
easily available information was provided by anamnestic
data on wheezing and nasal allergy; this also enabled to
define a group with a higher predictive value of FENO. As
number of sputum analyses was not very large and
recruited in a single practice of pneumologists, larger
multi-center investigations could be helpful to further
clarify the issue and optimise the use of FENO in clinical
practice under different conditions.
There are a number of limitations regarding our study. We
could not check the diagnoses after 12 months with repeated
bronchoprovocation, mainly due to ethical reasons since
many patients had been diagnosed as not having airway dis-
ease. In 33 patientswith a diagnosis of asthmaupon inclusion,
patients and doctors agreed after 12months that asthmawas
not present. On the first sight, this seems to challenge the
definition of asthma. It is, however, well known that also
bronchoprovocation is not the perfect “gold standard” to
establish the diagnosis of asthma. False positive diagnoses
might result because of post-infectious BHR, gastro-
esophageal reflux disease, allergic rhinitis and many more
[5,18]. Therefore, the positive predictive value is calculated
as 70% when a pre-test probability of 30% for asthma is given
[5], due to the Bayesian Theorem [18]. This corresponds to
our results as 79 (71%) of the 112 patients with asthma at
inclusion (t0) still suffered from asthma at twelve months
follow-up (t1). For FENO, the dependence of predictive
values on pre-test probabilities has been worked out by
Berkman before [21]. In this 24-month follow-up study FENO
was as good as methacholine bronchoprovocation. However,
their optimal cut-off value was 7 ppb due to the higher flow-
rate used (250 ml/s). In the present study patients who did
not respond to the follow-up request were younger. Their
mean FENO at t0 was higher and they had more often the
diagnosis of asthma but the difference to the participants in
t1 was not statistically significant. This could have led to an
underestimation of the usefulness of FENO, as lower preva-
lence would result in lower positive predictive values. The
ROC results regarding the diagnostic accuracy in eosinophilic
and non-eosinophilic asthma should not be hampered by this.
The advantage of the delayed-type of diagnostic study design
allowed revealing that FENO measurement can be superioreven to bronchoprovocation, at least in eosinophilic asthma.
Only a third of follow-up patients had delivered spontaneous
sputum, which could have biased the results. However, we
found no cues that these patients showed more severe dis-
ease than the others [11].
To conclude, it seems worth the effort to optimise the
strategies for an efficient use of FENO in primary care set-
tings, particularly for asthma. To consider FENO for choosing
steroid therapy is well supported in eosinophilic asthma [22],
but also applies to asthma in general [19]. GP and pneu-
mologist can use FENO to decide whether steroid therapy
should be tried, and a reasonable cut-off might be about
45 ppb [22,23]. In primary care, the predictive value of FENO
still is not fully satisfying and should be improved by iden-
tifying subgroups of patients, in whom FENO is most infor-
mative, ideally on the basis of medical history. Probably the
strategy should be different for the pneumologist employing
bronchoprovocation and possibly even sputum analysis, and
the GP for whom both methods are not directly accessible.
Our findings also suggest that it is worthwhile to assess the
diagnostic value of FENO not only against the assessments
performed at the time of diagnosis but also against follow-up
data that render the diagnosis more accurate.Conflicts of interest
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